Clinical Trial Update: A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis [Phase 1]

View source ↗

Summary

An update on a Phase 1 study evaluating subcutaneous ocrelizumab in people with multiple sclerosis, focusing on pharmacokinetics, safety, and tolerability; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ocrevus (ocrelizumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Multiple Sclerosis (MS) | Phase 1 | Status: COMPLETED